Interview with the Innovators

Supported by BridgeBio

Maneuvering the Complexity of Amyloidosis Diagnosis
Cindy Bither, RN, MSN, ANP-C, ACNP-C, CHFN, discusses the complexity of amyloidosis and offers strategies on how to raise awareness of the disease.

Tools to Diagnose and Monitor ATTR-CM
During this discussion, transthyretin amyloidosis specialists will be outlining the diagnostic and prognostic tools that are utilized to help guide treatment decisions for ATTR-CM.

Evolving Approaches to Transthyretin Stabilization for Cardiac ATTR
Amyloidosis News presents a discussion on the evolving approaches to transthyretin stabilization for cardiac ATTR. Transthyretin amyloid specialists, Keyur B. Shah, MD, Section Chief of Heart Failure, Virginia Commonwealth University Health and Michel Khouri, MD, Associate Professor of Medicine in Cardiology, Duke University review cardiac ATTR mechanism of disease and discuss proven and potential approaches to TTR stabilization.

Utility of Functional Assessments in the Prognosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas TX, explain the usefulness of the six-minute walk test in clinical practice and to patients.

The Importance of Early Diagnosis in ATTR-CM

Addressing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Through Preservation of Transthyretin
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, review the rationale for stabilization as the optimal approach to addressing transthyretin amyloid cardiomyopathy.

The Journey to Diagnosing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Doesn’t Have to Be a Long One
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, discuss the debilitating disease burden and the pathway to transthyretin amyloid cardiomyopathy diagnosis.

Transthyretin (TTR) Protein in Humans: Stabilization vs Destabilization
In this first video clip, Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX, describe the functions of transthyretin (TTR) in its naturally occurring tetrameric form and resulting damage from TTR destabilization.

Serum Transthyretin in the Management of TTR Amyloidosis
Justin L. Grodin, MD, MPH, Assistant Professor of Medicine, UT Southwestern Medical Center, Dallas, TX, explains the current and potentially future utilities of serum transthyretin (sTTR) as a biomarker in the management of transthyretin amyloidosis.

Setting Realistic Treatment Goals and Expectations for Patients with Transthyretin Amyloidosis
Ola Akinboboye, MD, MPH, MBA, Clinical Professor, Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health and Medical Director, Laurelton Heart Specialists PC (Rosedale, NY) and Clement C. Eiswirth, Jr., MD, FACC, Medical Director, Cardiomyopathy and Heart Failure Program, Ochsner Health, New Orleans, LA, highlight the importance of early diagnosis and realistic expectations for patients being treated for transthyretin amyloidosis.

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.